Navigation Links
CorMedix Receives Minutes from Neutrolin Pre-IND Meeting with FDA
Date:12/23/2013

Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: risks of launch and market acceptance of our products; obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix's product candidates; the risks and uncertainties associated with CorMedix's ability to manage its limited cash resources; obtaining additional financing to support CorMedix's research and development and clinical activities and operations; CorMedix's ability to maintain its listing on the NYSE MKT; the outcome of clinical trials of CorMedix's product candidates and whether they demonstrate these candidates' safety and effectiveness; CorMedix's ability to enter into and maintain collaborations with third parties for its development programs; CorMedix's dependence on its collaborations and its license relationships; achieving milestones under CorMedix's collaborations; CorMedix's dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statement
'/>"/>
SOURCE CorMedix Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CorMedix to Report Third Quarter Financial Results on November 19, 2013
2. CorMedix Inc. Closes $3,000,000 Preferred Stock Offerings
3. CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union
4. CorMedix Reports Second Quarter 2013 Results
5. CorMedix Granted Extension of NYSE MKT Listing
6. Philips receives FDA clearance for First-Ever Spectral Breast Density Measurement Application
7. Caris Life Sciences Receives Tumor Profiling Industrys First ISO 15189 Medical Laboratory Accreditation
8. Synapse Biomedical Receives $2.4 Million
9. Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
10. Mobius Imaging Receives ISO 13485 Certification
11. Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  Avanir Pharmaceuticals, ... the U.S. Food and Drug Administration (FDA) has ... Drug Application (NDA) for AVP-825. AVP-825 is an ... powder delivered intranasally utilizing a novel Breath Powered ... Response letter, and consistent with the preliminary feedback ...
(Date:11/26/2014)... N.Y. , Nov. 26, 2014  BioScrip ® , Inc. ... Smith , President and Chief Executive Officer, will present at the ... , , , Date: , , , Wednesday, ... , 2:50 p.m. EST , , , , Location: , ... About BioScrip, Inc. BioScrip, ...
(Date:11/26/2014)... Nov. 26, 2014  Aridis Pharmaceuticals, Inc., a ... therapies for infectious diseases, announced today the addition ... recognized key opinion leader in the areas of ... board. Founder and Chief Executive Officer, ... Dr. Opal,s extensive experience investigating bacterial toxins and ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... WIRE)--Apr 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) ... results from the Phase III clinical trial,evaluating ... ALTACE(R),(ramipril) diuretic fixed-dose combination product. The Company ... expects to present the,findings in detail at ...
... AACR Highlight Progress in SuperGen's,Oncology-Focused Pre-Clinical Pipeline, ... SuperGen,Inc. today announced that MP470, its multi-targeted ... critical component of,double- stranded DNA repair in ... of,presentations at the 2007 American Association for ...
Cached Medicine Technology:King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide 2Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 2Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 3Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 4Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 5Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 6Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 7
(Date:11/27/2014)... Blood-borne pathogens raise the risk of spreading diseases, ... place to counter this. However, it doesn’t seem as ... menstrual blood are taken as seriously. , "This ... to handle tampons and menstrual pads while also protecting ... He then created a prototype of the Sani-M, an ...
(Date:11/27/2014)... 2014 "As a nurse I see ... of urinary incontinence," said an inventor from Whiting, N.J. ... specialized accessory to prevent leakage and keep them dry ... urine leakage. This prevents stains on pants, skirts and ... pad ensures that the individual has time to get ...
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 (HealthDay ... second language, new research suggests. But anyone who tries to ... boost, the small study finds. The brain "becomes ... Li, co-director of the Center for Brain, Behavior and Cognition ... said, that "the brain networks of the more successful learners ...
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola vaccine appears to be safe and produces an ... virus, according to early clinical trial results reported by the ... phase I clinical trial for the vaccine paves the way ... Liberia and Sierra Leone as early as January, said Dr. ...
(Date:11/27/2014)... November 27, 2014 In order to enable ... Sharpes, Fla., designed an easy way to avoid touching a ... He then created a prototype of the patent-pending Toilet Tamer, ... a toilet seat and/or lid in a more sanitary manner. ... spread of germs. Overall, it promotes good hygiene and peace ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3
... infections occuring more often than previously believed, study finds ... drug-resistant staph infections are more common, both in and ... study warns. , Methicillin-resistant Staphylococcus aureus (MRSA) infections are ... among people in hospitals and can result in severe ...
... Even though Americans pick up their,toothbrushes for a ... cleaning of their own. Celebrity Dentist Dr. Bill Dorfman ... survey conducted by the,Philips Sonicare brand shows dirty brushes ... this report from Philips (NYSE: PHG ) at:, ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... today announced that it has,scheduled a conference call and ... ET to discuss operating results for the third quarter ... issue its financial news,release the morning of November 1 ...
... Request Highlights December 2 Annual Wells Fargo Walk of Ages ... ... is,inviting everyone with the name of "Walker" in the United States to either,join ... of,Ages" on December 2 in Reseda. According to official census records there,are 663,233 ...
... Oct. 16 Young Innovations, Inc.,(Nasdaq: YDNT ) ... results with a live and on-demand web cast conference ... Time. A live audio,broadcast of the call will be ... live audio broadcast,will also be available through the Company,s ...
... SYMBOL - BCL.P, VANCOUVER, Oct. 16 ... to announce that it has entered into ... 2007 (the "Arrangement,Agreement") with iCo Therapeutics Inc. ... will constitute Beanstalk,s,"Qualifying Transaction" as a capital ...
Cached Medicine News:Health News:Drug-Resistant Staph a Widespread Threat 2Health News:Drug-Resistant Staph a Widespread Threat 3Health News:Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007 2Health News:Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007 3Health News:FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named 'Walker' in the United States 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 3Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 4Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 5Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 6Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 7Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 8Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 9Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 10
... temporary internal drainage from the ... Supplied sterile in peel-open packages. ... Periodic evaluation is advised; polyurethane, ... not remain indwelling more than ...
... for temporary internal drainage from ... bladder. Supplied sterile in peel-open ... CAUTION: Periodic evaluation is advised; ... must not remain indwelling more ...
... Used for catheter or instrument introduction. ... to be peeled away and removed. ... or instrument to be introduced should ... through the sheath. Supplied sterile in ...
... Used to provide ... or epispadias repair. The ... to partially close during ... urethra while maintaining urethral ...
Medicine Products: